1. Osaka Rheumatology Clinic, Osaka, Japan;
2. Department of Molecular Regulation for Intractable Diseases, Institute of Medical Science, Tokyo Medical University, Tokyo, Japan;
3. Department of Radiology, Kansai Rosai Hospital, Hyogo, Japan;
4. National Hospital Organization Kinki Chuo Chest Medical Center, Osaka, Japan;
5. Department of Rheumatology and Allergology, National Hospital Organization, Osaka Minami Medical Center, Osaka, Japan;
6. Department of Chemotherapy, Osaka University Hospital, Osaka, Japan;
7. Department of Diagnostic Pathology and Cytology, Osaka International Cancer Institute, Osaka, Japan;
8. Chugai Pharmaceutical Co., Ltd., Tokyo, Japan; and Safety Evaluation Committee of tocilizumab for Castleman disease